Therapeutic Targeting of PELP1 Prevents Ovarian Cancer Growth and Metastasis
- 14 April 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (8) , 2250-2259
Abstract
Purpose: Ovarian cancer remains a major threat to women's health, partly due to difficulty in early diagnosis and development of metastases. A critical need exists to identify novel targets that curb the progression and metastasis of ovarian cancer. In this study, we examined whether the nuclear receptor coregulator PELP1 (proline-, glutamic acid-, leucine-rich protein-1) contributes to progression and metastatic potential of ovarian cancer cells and determined whether blocking of the PELP1 signaling axis had a therapeutic effect. Experimental Design: Ovarian cancer cells stably expressing PELP1-shRNA (short hairpin RNA) were established. Fluorescent microscopy, Boyden chamber, invasion assays, wound healing, and zymography assays were performed to examine the role of PELP1 in metastasis. Expression analysis of the model cells was conducted using tumor metastasis microarray to identify PELP1 Target genes. Therapeutic potential of PELP1-siRNA in vivo was determined using a nanoliposomal formulation of PELP1-siRNA-DOPC (1,2-dioleoyl-sn-glycero-3-phosphatidylcholine) administered systemically in a xenograft model. Results: PELP1 knockdown caused cytoskeletal defects and significantly affected the migratory potential of ovarian cancer cells. Microarray analysis revealed that PELP1 affected the expression of selective genes involved in metastasis including Myc, MTA1, MMP2, and MMP9. Zymography analysis confirmed that PELP1 knockdown caused a decrease in the activation of matrix metalloproteases (MMP) 2 and MMP9. Compared with control siRNA-DOPC–treated mice, animals injected with PELP1-siRNA-DOPC had 54% fewer metastatic tumor nodules, exhibited a 51% reduction in tumor growth and an 84% reduction in ascites volume. Conclusion: The results suggest that PELP1 signaling axis is a potential druggable target and liposomal PELP1-siRNA-DOPC could be used as a novel drug to prevent or treat ovarian metastasis. Clin Cancer Res; 17(8); 2250–9. ©2011 AACR.Keywords
This publication has 48 references indexed in Scilit:
- Cyclin-Dependent Kinase–Mediated Phosphorylation Plays a Critical Role in the Oncogenic Functions of PELP1Cancer Research, 2010
- Extranuclear Functions of ER Impact Invasive Migration and Metastasis by Breast Cancer CellsCancer Research, 2010
- The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtypeBreast Cancer Research and Treatment, 2009
- Therapeutic Targeting of ATP7B in Ovarian CarcinomaClinical Cancer Research, 2009
- The AIB1 Oncogene Promotes Breast Cancer Metastasis by Activation of PEA3-Mediated Matrix Metalloproteinase 2 (MMP2) and MMP9 ExpressionMolecular and Cellular Biology, 2008
- Oncogenic Potential of the Nuclear Receptor Coregulator Proline-, Glutamic Acid–, Leucine-Rich Protein 1/Modulator of the Nongenomic Actions of the Estrogen ReceptorCancer Research, 2007
- Functional and biological properties of the nuclear receptor coregulator PELP1/MNARNuclear Receptor Signaling, 2007
- Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian CarcinomaCancer Research, 2006
- Focal Adhesion Kinase Targeting UsingIn vivoShort Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma TherapyClinical Cancer Research, 2006
- AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian CancerScience, 1997